

WHO Drug Information

Volume 8, 1994: Index

A

ACE inhibitors, cardiac infarction, (1) 4
 nephropathy, (1) 4
 Acetylsalicylic acid, (4) 218
 antiplatelet therapy, (2) 45
 myocardial infarction, (1) 24
 Aciclovir, herpes zoster, (4) 203
 Adjuvant therapy, breast cancer, (1) 23
 cancer, (2) 58
 ADR information transfer, (1) 1
 Adverse drug-related events, information, (1), 1
 Adverse effects reporting, (4) 212
 Albendazole, (4) 197
 Albumin, placental derived, (1) 29
 Alpidem, hepatotoxicity, (2) 65
 Angiography, (4) 207
 Anthracyclines, (3) 143
 Antidepressants, hyponatraemia, (3) 152
 Antineoplastic agents, exposure, (1) 20
 Antiarrhythmic agents, (4) 213
 Azapropazone, (3) 153

B

BCG vaccine, (2) 46
 Bioethics, (3) 162
 Biphosphonate pamidronate, (3) 150
 Birth control, (4) 189
 Blood and plasma screening, (2) 65
 transmission, (3) 153
 Botulinum toxin, dysphagia, (2) 65
 Bovine spongiform encephalitis, (1) 29
 Bromocriptine, lactation, (3) 153

C

Caffeine, pregnancy, (2) 46
 Captopril, diabetic renal disease, (1) 30
 Carbamazepine, (4) 220
 Carotene supplementation, (1) 3
 Cell line management, (1) 24
 Clomiphene, (4) 200
 Clozapine, (2) 66
 myocarditis, (4) 212
 Contraceptives, oral, diabetes, (3) 135
 oral, ovarian cancer, (3) 136
 Corticosteroids, (4) 197
 chickenpox, (1) 34
 osteoporosis, (3) 149
 Counterfeits, (3) 154
 Cyproheptadine, (2) 66
 Cysticidal drugs, (4) 197

D

d-Sotalol, (4) 213
 Development of medicines, (4) 189
 Diarrhoeal disease, (1) 36
 Distribution practices, (1) 26
 Dithranol, (3) 162
 Donations, (4) 195
 Dornase alfa, cystic fibrosis, (1) 26
 Drug resistance, (4) 226
 pneumococcal infections, (3) 148
 Drugs secreted in human milk, (1) 21

E

Ergotamine, (4) 217
 Estrogen therapy, (2) 66
 breast cancer, (3) 137
 Ethical criteria for medicinal drug promotion, (3) 157
 Ethylene oxide, (2) 67
 European Pharmacopoeia, China, (3) 156

F

Factor VIII, (2) 50
 Felbamate, anaemia, (3) 154
 Fluoxetine, (4) 213
 Fluvoxamine, theophylline, (3) 156
 Furosemide, (4) 207

G

Gangliosides, (1) 31
 Good practices in drug distribution, (1) 26

H

Haemophilia treatment, (2) 50
 Hepatitis B vaccine, (2) 52
 High-lipase pancreatins, (2) 68
 HIV vaccine trials, (3) 152, (4) 213
 HIV vaccines, (3) 128
 Homoeopathic products, (2) 67
 Hydrocortisone, (1) 38

I

ICDRA, (2) 43
 IFPMA code of marketing practices, (3) 125
 Import procedures, guidelines, (4) 222
 Influenza vaccine, (4) 202
 formulations, (1) 32
 Interchangeability, (2) 71

International Nonproprietary Names (INN)

Proposed list **71**, (2) 85Proposed list **72**, (4) 227Recommended list **34**, (3) 165

Iron supplementation, pregnancy, (2) 54

L

L-asparaginase, (3) 143

L-tryptophan, depression, (1) 35

eosinophilia myalgia, (1) 18

Lactation, drugs, (1) 21

Lidocaine, (3) 134

Lipid-lowering agents, (4) 204

Lovastatin, (4) 204

M

Malaria vaccine, (1) 8, (4) 198

Management of leukemia, (3) 143

Mannitol, (4) 207

Manufacture of drugs, (1) 42

Mercaptopurine, (3) 143

Metformin hydrochloride, (1) 27

Methotrexate, (3) 143

Migraine and headache, (4) 215

Moxisylyte, hepatitis, (2) 67

Multi-source products, marketing, (2) 71

Multidrug-resistant tuberculosis, (2) 60

N

Neuroleptic sensitivity, (3) 155

Nicotine patches, (2) 68

Nicotine substitution, (3) 140

Nonoxynol-9, (1) 11

Nonsteroidal anti-inflammatory drugs, (3) 155

NSAIDs, (3) 155

O

Oral rehydration salts, (1) 36

Over-the-counter medicines, (4) 208

P

P-glycoproteins, (3) 145

Pancreatins, (2) 68

Paracetamol, (4) 219

Pentamidine, (1) 10

Phenformin hydrochloride, (1) 27

Pneumocystis prophylaxis, (1) 9

Post-marketing trials, guidelines, (1) 32

Pravastatin, (4) 204

Praziquantel, (4) 197

Prednisolone, (1) 39, (3) 143, (3) 150

Promotion, ethics, (3) 123

Psoriasis, (3) 161

Q

Quinine, tetanus, (4) 200

R

Remoxipride, (2) 69

Resistance, drug, (4) 226

pneumococcal infections, (3) 148

Rifabutin and uveitis, (1) 34

Rifampicin, fixed-dose combinations, (1) 27

Royal jelly, allergy, (1) 27

S

Safety of OTC products, (4) 208

Salicylic acid, (3) 162

Samples, drugs, (3) 156

Silicone oil, retinal reattachment, (4) 214

Simvastatin, (4) 204

Small-scale drug manufacture, (1) 42

Sotalol, (3) 134, (4) 213

Spermicides, (1) 11

Sulfasalazine, (1) 40

T

Tamoxifen, (1) 12, (2) 69

Tar products, (3) 162

Teratogenic risk, guidelines, (4) 210

Theophylline, fluvoxamine, (3) 156

Thymoxamine, (2) 70

Tiaprofenic acid, (3) 156

Tobacco control, (2) 63

Trimethoprim/sulfamethoxazole, (1) 10

V

Vaccination, (4) 190

Vaccine, BCG, (2) 46

hepatitis B, (2) 52

HIV, (3) 128, (4) 214, (3) 152

influenza, (4) 202

malaria, (1) 8, (4) 198

varicella, (1) 29

Varicella vaccine, (1) 29

Vincristine, (3) 143, (4) 214

Visceral leishmaniasis, (2) 60

Vitamin K, (1) 16

W

WHO Certification Scheme, USA/Russian

Federation, (1) 33

Z

Zidovudine, (2) 57, (3) 130

pregnancy, (3) 157

vertical transmission, (3) 130